B-Cell Lymphoma News

News

Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-cell Lymphoma

01/30/2024

Grace Taylor , MS, MA;

Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.

Jennifer L. Crombie, MD, and...

01/30/2024

Journal of Clinical Pathways

News

Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel and Tisagenlecleucel for Third-Line or Later Treatment for R/R DLBCL

09/12/2023

Grace Taylor , MS, MA;

Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.

Researchers compared the cost of...

09/12/2023

Journal of Clinical Pathways

News

NCCN Updates Clinical Practice Guidelines for B-Cell Lymphomas

08/30/2023

Grace Taylor , MS, MA;

NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.

NCCN recently published updated...

08/30/2023

Journal of Clinical Pathways

News

The Impact of Demographic Factors on Time to Diagnosis for Patients With Diffuse Large B-Cell Lymphoma

08/03/2023

Grace Taylor , MS, MA;

Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).

Researchers investigated how...

08/03/2023

Journal of Clinical Pathways

News

Analysis of Racial Disparities in Cancer-Specific Survival Rates of Patients with Diffuse Large B-Cell Lymphoma

07/06/2023

Grace Taylor , MS, MA;

In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.

In a recent study, Soyon Lee,...

07/06/2023

Journal of Clinical Pathways

News

New Standard Treatment Approach for Patients With DLBCL

10/17/2020

Journal of Clinical Pathways

News

Evaluating Neutropenia Prevalence After Venetoclax Therapy for CLL

06/23/2020

A study at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020) evaluated fixed duration venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...

A...

06/23/2020

Journal of Clinical Pathways

News

Long-Term Follow-Up of BTK Inhibitor in Symptomatic Treatment-Naïve CLL

06/15/2020

Long-term data from ACE-CL-001 further supports the favorable results of acalabrutinib in phase III studies for patients with symptomatic, treatment-naïve chronic lymphocytic leukemia (CLL). Results of the study...

...

06/15/2020

Journal of Clinical Pathways

News

Venetoclax-Based Time-Limited Therapy Well Tolerated, Effective in CLL

06/10/2020

Zanubrutinib plus venetoclax and obinutuzumab is well tolerated and achieves rapid undetectable minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL), according to a presentation at the...

...

06/10/2020

Journal of Clinical Pathways

News

Practice Patterns, Predictors of Survival for Older Patients With MCL

05/27/2020

A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...

A new...

05/27/2020

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

B-Cell Lymphoma News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products